Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
Cidara Therapeutics (CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies through its proprietary Cloudbreak® platform, has scheduled its first quarter 2025 financial results announcement for May 8, 2025. The results will be released after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time to discuss financial performance and provide operational updates.
Cidara Therapeutics (CDTX), un'azienda biotecnologica specializzata in immunoterapie coniugate farmaco-Fc tramite la sua piattaforma proprietaria Cloudbreak®, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per l'8 maggio 2025. I risultati saranno diffusi dopo la chiusura del mercato statunitense, seguiti da una conference call e webcast alle 17:00 ora Eastern per discutere le performance finanziarie e fornire aggiornamenti operativi.
Cidara Therapeutics (CDTX), una empresa biotecnológica especializada en inmunoterapias conjugadas de fármaco-Fc mediante su plataforma patentada Cloudbreak®, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025. Los resultados se publicarán después del cierre del mercado estadounidense, seguidos de una llamada conferencia y webcast a las 5:00 PM hora del Este para discutir el desempeño financiero y proporcionar actualizaciones operativas.
Cidara Therapeutics (CDTX)는 독자적인 Cloudbreak® 플랫폼을 통해 약물-Fc 접합 면역치료제를 전문으로 하는 생명공학 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 8일로 예정했습니다. 실적은 미국 시장 마감 후 발표되며, 이후 동부 표준시 오후 5시에 재무 성과 및 운영 업데이트를 논의하는 컨퍼런스 콜과 웹캐스트가 진행됩니다.
Cidara Therapeutics (CDTX), une société de biotechnologie spécialisée dans les immunothérapies conjuguées médicament-Fc via sa plateforme propriétaire Cloudbreak®, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour le 8 mai 2025. Les résultats seront publiés après la clôture du marché américain, suivis d'une conférence téléphonique et d'un webcast à 17h00 heure de l'Est pour discuter des performances financières et fournir des mises à jour opérationnelles.
Cidara Therapeutics (CDTX), ein Biotechnologieunternehmen, das sich auf Wirkstoff-Fc-Konjugat-Immuntherapien mittels seiner proprietären Cloudbreak®-Plattform spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 geplant. Die Ergebnisse werden nach Handelsschluss in den USA veröffentlicht, gefolgt von einer Telefonkonferenz und einem Webcast um 17:00 Uhr Eastern Time, um die finanzielle Leistung zu besprechen und betriebliche Updates zu geben.
- None.
- None.
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, May 8, 2025 |
| Time: | 5:00 PM Eastern Time |
| United States: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Conference ID: | 90743 |
| Webcast: | Link |
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) release Q1 2025 earnings?
How can investors join Cidara Therapeutics (CDTX) Q1 2025 earnings call?
What is Cidara Therapeutics' (CDTX) main technology platform?
Is this Cidara Therapeutics' (CDTX) first quarterly earnings call?
